Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (581-590 of 934) with videos related to

Pageof 94
Sort By:
American Heart Journal|April 30, 2017
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics, L Bowman, F Chen, et al.
The New England Journal of Medicine|March 10, 2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromesChristopher P Cannon, Eugene Braunwald, Carolyn H McCabe, et al.
Critical Pathways in Cardiology|March 15, 2008
Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: a report from TACTICS-TIMI 18Aaron D Kugelmass, Saihari Sadanandan, Nasser Lakkis, et al.
The New England Journal of Medicine|October 31, 1996
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromesE M Antman, M J Tanasijevic, B Thompson, et al.
Kidney International Reports|April 18, 2023
Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) TrialDavid Z I Cherney, Francesco Cosentino, Darren K McGuire, et al.
The American Journal of Medicine|July 4, 2012
Age and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarctionSripal Bangalore, Gregg C Fonarow, Eric D Peterson, et al.
Atherosclerosis|July 27, 2019
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus controlAntonio J Vallejo-Vaz, Kausik K Ray, Henry N Ginsberg, et al.
American Heart Journal|January 28, 2010
Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarctionJames R Harkness, Marc S Sabatine, Eugene Braunwald, et al.
American Heart Journal|April 30, 1999
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 InvestigatorsF Van de Werf, C P Cannon, A Luyten, et al.
Journal of the American College of Cardiology|December 1, 1994
Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC P Cannon, C H McCabe, D J Diver, et al.
Pageof 94

Showing results (581-590 of 934) with videos related to

Sort By:
Pageof 94
American Heart Journal|April 30, 2017
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics, L Bowman, F Chen, et al.
The New England Journal of Medicine|March 10, 2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromesChristopher P Cannon, Eugene Braunwald, Carolyn H McCabe, et al.
Critical Pathways in Cardiology|March 15, 2008
Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: a report from TACTICS-TIMI 18Aaron D Kugelmass, Saihari Sadanandan, Nasser Lakkis, et al.
The New England Journal of Medicine|October 31, 1996
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromesE M Antman, M J Tanasijevic, B Thompson, et al.
Kidney International Reports|April 18, 2023
Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) TrialDavid Z I Cherney, Francesco Cosentino, Darren K McGuire, et al.
The American Journal of Medicine|July 4, 2012
Age and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarctionSripal Bangalore, Gregg C Fonarow, Eric D Peterson, et al.
Atherosclerosis|July 27, 2019
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus controlAntonio J Vallejo-Vaz, Kausik K Ray, Henry N Ginsberg, et al.
American Heart Journal|January 28, 2010
Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarctionJames R Harkness, Marc S Sabatine, Eugene Braunwald, et al.
American Heart Journal|April 30, 1999
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 InvestigatorsF Van de Werf, C P Cannon, A Luyten, et al.
Journal of the American College of Cardiology|December 1, 1994
Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC P Cannon, C H McCabe, D J Diver, et al.
Pageof 94